Global Cord Blood (NYSE:CO) Earns Strong-Buy Rating from Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Global Cord Blood (NYSE:CO) in a research report issued to clients and investors on Thursday. The brokerage set a “strong-buy” rating on the medical research company’s stock.

Global Cord Blood Stock Performance

Shares of CO stock opened at $1.50 on Thursday. Global Cord Blood has a 52-week low of $2.03 and a 52-week high of $5.50. The stock has a market cap of $182.33 million, a price-to-earnings ratio of 2.34 and a beta of 0.16. The firm’s 50-day moving average is $1.47 and its 200-day moving average is $1.35.

About Global Cord Blood

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.